
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc's innovative approach in targeting the transferrin receptor (TfR) for neurodegenerative treatments demonstrates substantial potential, with its ABC platform showing impressive brain uptake rates of 18-32 times in non-human primates while maintaining favorable safety profiles. The firm's pipeline, which includes promising candidates like AL137 and AL050, aims to tackle significant indications in Alzheimer’s disease and Parkinson’s, enhancing the likelihood of successful clinical outcomes supported by standardized AD biomarkers. Additionally, the potential for early clinical proof-of-concept data from these programs could provide considerable upside for shareholder value, further solidifying a positive outlook on the company’s prospects.
Bears say
Alector Inc. faces significant headwinds due to the failure of its INFRONT-3 trial for latozinemab, which did not meet its primary endpoint and raises concerns about the efficacy of the company's therapeutic approach to neurodegeneration. This result introduces translational biology risks and highlights the inefficiency of PGRN transport, which undermines investor confidence in the potential success of other pipeline products such as AL001 and AL002. Additionally, ongoing clinical trials present company-specific risks that could further delay regulatory approvals and hinder the anticipated commercial revenue, contributing to a negative outlook for Alector's stock.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares